NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated August 1, 2026

Supplement × Prescription·Evidence index

Ivabradine and Potassium: what the published research says

PubMed indexes 6 records that name Ivabradine and Potassium together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.

Read this first

An evidence index, not guidance.

Every statement below is attributed to a named, dated, linked source.

This page lists published research relevant to Ivabradine and Potassium. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.

The research

6 studies naming Ivabradine and Potassium.

Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.

hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.

Journal of the American Heart Association · 2015 · PMID 25911606

Human subjects

“Ivabradine prolongs ventricular repolarization and alters electrical restitution properties at concentrations relevant to the upper therapeutic range. In absolute terms ivabradine does not discriminate between hERG and HCN channels: it inhibits Ih ERG with similar potency to that reported for native If and HCN channels, with S6 binding determinants resembling those observed for HCN4.”

Melgari et al. · Authors' conclusion

Names both Ivabradine and Potassium in its title.

Ivabradine: new drug. Best avoided in stable angina.

Prescrire international · 2007 · PMID 17458043

Comparative StudyHuman subjects704 participants

“(7) Ivabradine is metabolised by cytochrome P450 isoenzyme CYP 3A4; there is therefore a potentially high risk of pharmacokinetic interactions. (8) In practice, for long-term preventive treatment of angina it is better to avoid ivabradine and to use better-documented treatments: preferably a betablocker, or, if a betablocker cannot be used, verapamil or amlodipine.”

From the abstract

Names Ivabradine and Potassium together in an interaction, co-administration, or pharmacokinetic context.

Limitations

What this evidence cannot tell you.

Search-based evidence indexes have real limits, and it is worth being explicit about them:

NutriStack

Track what you actually take.

NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Ivabradine, Potassium, and several hundred other substances.

The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.